Project Grant R01HL178823
Award Date
7/1/25
Completion Date
3/31/29
Dollars Obligated
$677K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $759,983 to the University of North Carolina at Chapel Hill to conduct research examining the diverse responses of neutrophils during Streptococcus pneumoniae pneumonia and acute lung injury. The research aims to determine the changes that neutrophils undergo as they are recruited and carry out their functions during pneumonia,...
This Project Grant award, titled "ADAPTIVE IMMUNITY TO ASPERGILLUS DURING NEUTROPENIA", is funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $119,082 award, effective August 15, 2024 through July 31, 2026, supports research at Brigham & Women's Hospital to investigate how neutrophils influence the development of adaptive immunity to the fungal pathogen Aspergillus in hosts with neutropenia. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996.00 to the University of Southern California to investigate the role of the PDLIM2 protein in regulating alveolar macrophage function and its impact on lung innate immunity, inflammation, and disease pathogenesis. The research aims to elucidate how PDLIM2 modulates alveolar macrophage phagocytosis, immune response, and...
This Project Grant award, with funding of $615,455 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of eosinophils in promoting antibacterial immunity against Streptococcus pneumoniae during viral-bacterial co-infections. The key objectives are to: 1) determine the mechanisms and outcomes of interactions between eosinophils and Streptococcus pneumoniae, and 2) elucidate how these...
This federal Project Grant award, valued at $2,000,987.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to examine how the innate antiviral immune response and associated metabolic changes in the respiratory epithelium facilitate viral-bacterial co-infections by Pseudomonas aeruginosa in cystic fibrosis. The primary awardee, Trustees of Dartmouth College, will use an improved model of P....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support research to identify the role of myeloid-derived suppressor cells (MDSC) in the immune response of children with severe viral lower respiratory tract infections (LRTI). The $180,199 award, effective September 1, 2024 through August 31, 2029, will enable the Research Institute at Nationwide Children's Hospital to...
This federal Project Grant award of $445,000.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research focused on understanding the role of neutrophil extracellular traps (NETs) in thromboinflammatory diseases. The research aims to characterize the immune homeostasis functions of NETs, define the mechanisms by which the platelet factor 4 (PF4) protein and an anti-PF4 antibody can enhance NET-mediated bacterial...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $177,721 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Brigham & Women's Hospital Inc. The grant will fund a 5-year research project led by Dr. Nicole Prince, a biochemist with expertise in molecular epidemiology, to investigate the biological determinants underlying respiratory infection risk in children, a leading cause of childhood...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $322,480 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of endothelial sphingosine-1-phosphate receptor 1 (S1PR1) in promoting lung repair after viral infections that lead to acute respiratory distress syndrome (ARDS). The research aims to define the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,063,324 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Tulane University. The grant, awarded on June 5, 2025, will support research to investigate the metabolic requirements and survival mechanisms of lung and nasal tissue-resident memory CD4+ T cells, and their interactions with lung fibroblasts, to enhance the understanding of pulmonary host defenses against respiratory pathogens. The research...